External study possibilities of a dead body solution about the death occurrence from psychotropic and narcotic drug poisoning

Background: Poisoning with psychotropic and narcotic substances is still leads to the general structure of fatal intoxications. A decreased traditional psychotropic and narcotic drug fatal poisoning and an increased new synthetic psychoactive substances and combined consumption are recorded in the country. Aims: This study aimed to study the dynamics of drug poisoning incidence according to the annual report data in 20172020 in the Krasnodar territory and establish their predominant etiology. Analyze the medical literature and identify the data mostly described during the external examination that suggests narcotic drug exposure possibility of the body. Comparison of the literature and external examination results of the corpse from the Expert Conclusions (Acts of forensic medical research) to further use the signs to create a profile of the suspected poisoned corpse with narcotic substances. Material and methods: The study material includes the annual reports of the State Budgetary Healthcare Institution Bureau SME of the Ministry of Health of the Krasnodar Territory in 20172020, archival medical documentation autopsy reports in cases of death from narcotic substances; domestic and foreign literary sources. Results: In the Krasnodar Territory, opiates account for a large proportion of drug deaths. Psychotropic and narcotic drug intake is often (up to 30%) combined with alcohol consumption. The study showed that forensic pathology rarely uses external signs that make up the profile of a corpse suspected of drug poisoning at the initial stage. The most common signs (in 50% of cases) were: injection traces, cyanotic and flushed face, conjunctival hemorrhages, and whitish-pink foam in the nose or mouth openings. Others were not given due attention. Conclusion: The research topic dictates the need for further study and problem development, accumulation, and systematization of the obtained material for subsequent use.

A Wider Range of Conditions Contributing to Death in a Cohort of People Who Have Injected Drugs. Findings from an Edinburgh Cohort.

BackgroundThe morbidity and mortality attributed to injecting drug use is a substantial contributor to any study on causes of premature death. Understanding the extent of this may be limited by difficulties in observing and recording outcomes over several decades. Historic studies have recorded information in a period when blood borne virus and drug deaths were a smaller proportion or, in the cases of Hepatitis C and HIV/AIDS, absent from National mortality figures.Design and settingA cohort of people who had, ever, injected drugs was established over a prolonged period of observation in one, community based, medical practice in Edinburgh (UK). Outcomes were measured in the clinical situation and by accessing death certificates from national, UK, registers.FindingsCauses of death in a cohort of 794 people who inject drugs (PWIDs) varied over time, some conditions relating to single pathological diagnoses and others were more complicated, multimorbid, and cumulative over time. HIV/AIDS was a striking cause of death until 1995 when antiviral chemotherapy was introduced. Drug related deaths (mainly overdose) remained a significant cause of death and death due to alcohol, respiratory, cardiovascular and cancer (mainly lung) increased over time. A wide range of other causes including suicide and violence and trauma were recorded.ConclusionsMortality resulting from present or historic drug use may be underestimated in current recoding systems, which largely record deaths from overdose or a single pathological event in an acute situation. The range of conditions causing or contributing to premature death is enormous reflecting multiple risks associated with drug use.

Geographical Aspects of Recent Trends in Drug-Related Deaths, with a Focus on Intra-National Contextual Variation

Background. Recent worldwide estimates are of 53 million users of opioids annually, and of 585,000 drug-related deaths, of which two thirds are due to opioids. There are considerable international differences in levels of drug death rates and substance abuse. However, there are also considerable variations within countries in drug misuse, overdose rates, and in drug death rates particularly. Wide intra-national variations characterize countries where drug deaths have risen fastest in recent years, such as the US and UK. Drug deaths are an outcome of drug misuse, which can ideally be studied at a relatively low spatial scale (e.g., US counties). The research literature suggests that small area variations in drug deaths to a considerable degree reflect contextual (place-related) factors as well as individual risk factors. Methods. We consider the role of area social status, social cohesion, segregation, urbanicity, and drug supply in an ecological regression analysis of county differences in drug deaths in the US during 2015–2017. Results. The analysis of US small area data highlights a range of factors which are statistically significant in explaining differences in drug deaths, but with no risk factor having a predominant role. Comparisons with other countries where small area drug mortality data have been analyzed show differences between countries in the impact of different contextual factors, but some common themes. Conclusions. Intra-national differences in drug-related deaths are considerable, but there are significant research gaps in the evidence base for small area analysis of such deaths.

US life expectancy stalls due to cardiovascular disease, not drug deaths

After decades of robust growth, the rise in US life expectancy stalled after 2010. Explanations for the stall have focused on rising drug-related deaths. Here we show that a stagnating decline in cardiovascular disease (CVD) mortality was the main culprit, outpacing and overshadowing the effects of all other causes of death. The CVD stagnation held back the increase of US life expectancy at age 25 y by 1.14 y in women and men, between 2010 and 2017. Rising drug-related deaths had a much smaller effect: 0.1 y in women and 0.4 y in men. Comparisons with other high-income countries reveal that the US CVD stagnation is unusually strong, contributing to a stark mortality divergence between the US and peer nations. Without the aid of CVD mortality declines, future US life expectancy gains must come from other causes—a monumental task given the enormity of earlier declines in CVD death rates. Reversal of the drug overdose epidemic will be beneficial, but insufficient for achieving pre-2010 pace of life expectancy growth.